Verastem (NASDAQ: VSTM) received a significant upgrade from BTIG Research, which has now classified the biopharmaceutical company as a “strong-buy.” This announcement was made in a note distributed to investors on March 4, 2024. The upgrade reflects growing confidence in Verastem’s future performance among analysts in the financial sector.
Alongside BTIG’s upgrade, several other investment firms have also expressed positive sentiments towards Verastem. Jefferies Financial Group reiterated a “buy” rating, setting a target price of $19.00 for the company’s shares. Similarly, HC Wainwright commenced coverage with a “buy” rating and an $18.00 price objective on February 4, 2024. Notably, Wall Street Zen revised its stance on Verastem from “sell” to “hold” just a few days later. Mizuho also established a target price of $18.00 on February 19, 2024.
Despite the positive feedback from many analysts, Weiss Ratings maintained a more cautious approach, reaffirming a “sell (d-)” rating on January 21, 2024. The overall consensus from investment analysts indicates that three have rated the stock as a strong buy, five have given it a buy rating, one assigned a hold rating, and another issued a sell rating. According to MarketBeat.com, Verastem currently holds an average rating of “buy” with a target price of approximately $16.83.
Recent Earnings and Stock Performance
Verastem recently reported its quarterly earnings on March 4, 2024. The company posted an earnings per share (EPS) of ($0.50), missing analysts’ expectations of ($0.49) by a narrow margin. The company recorded revenues of $17.54 million for the quarter, exceeding the analyst estimate of $16.85 million. Research analysts forecast that Verastem will report an average EPS of ($3.02) for the current fiscal year.
Despite the positive revenue report, the company’s stock experienced a decline of 4.1% following the earnings announcement.
Insider Transactions and Institutional Investments
In other developments, insider trading activity at Verastem reveals that CEO Dan Paterson sold 10,321 shares on January 12, 2024, at an average price of $7.16, totaling approximately $73,898.36. After this sale, Paterson retained ownership of 400,104 shares, valued at around $2.86 million. This transaction represented a 2.51% reduction in his holdings.
Additionally, CFO Daniel Calkins sold 5,039 shares on the same day for about $36,079.24, resulting in a 4.59% decrease in his position, leaving him with 104,719 shares valued at $749,788.04. Over the past ninety days, insiders have sold a total of 17,678 shares worth approximately $128,685. Collectively, insiders own 2.10% of Verastem’s stock.
Institutional interest in Verastem has also seen notable activity. Polar Capital Holdings Plc significantly increased its stake by 270.7% during the fourth quarter, acquiring an additional 2,866,350 shares, bringing its total holdings to 3,925,126 shares valued at $30.3 million. Other institutional investors, including Armistice Capital LLC and Farallon Capital Management LLC, have also made substantial investments, reflecting a growing institutional confidence in Verastem.
Verastem Oncology, Inc., founded in 2010 and based in Needham, Massachusetts, focuses on developing small molecule therapies targeting cancer stemness and resistance pathways. The company adopts a precision-medicine approach, aiming to identify critical signaling pathways that contribute to tumor growth and relapse, particularly in hematologic malignancies and solid tumors. Its lead product, COPIKTRA (duvelisib), is an oral inhibitor that has gained recognition in the field.
As Verastem continues to navigate the complexities of the biopharmaceutical landscape, the recent analyst upgrades and insider activities could signal a pivotal moment in its growth trajectory.
